BRPI0924078A2 - n-glicanos contendo galactose-alfa-1,3-galactose em produtos de glicoproteína derivados de células de cho. - Google Patents

n-glicanos contendo galactose-alfa-1,3-galactose em produtos de glicoproteína derivados de células de cho.

Info

Publication number
BRPI0924078A2
BRPI0924078A2 BRPI0924078A BRPI0924078A BRPI0924078A2 BR PI0924078 A2 BRPI0924078 A2 BR PI0924078A2 BR PI0924078 A BRPI0924078 A BR PI0924078A BR PI0924078 A BRPI0924078 A BR PI0924078A BR PI0924078 A2 BRPI0924078 A2 BR PI0924078A2
Authority
BR
Brazil
Prior art keywords
galactose
alpha
cho cell
cell derived
glycans containing
Prior art date
Application number
BRPI0924078A
Other languages
English (en)
Inventor
Bosques Carlos
Liu Cuihua
Sarvaiya Hetal
Murphy Jennifer
Washburn Nathaniel
Xu Xiao-Jin
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40524730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0924078(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of BRPI0924078A2 publication Critical patent/BRPI0924078A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/0609Oocytes, oogonia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/24Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25125Digestion or removing interfering materials
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/25Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25375Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0924078A 2009-01-22 2009-01-22 n-glicanos contendo galactose-alfa-1,3-galactose em produtos de glicoproteína derivados de células de cho. BRPI0924078A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/031678 WO2010085251A1 (en) 2009-01-22 2009-01-22 Galactose-alpha-1, 3-galactose-containing n-glycans in glycoprotein products derived from cho cells

Publications (1)

Publication Number Publication Date
BRPI0924078A2 true BRPI0924078A2 (pt) 2018-10-16

Family

ID=40524730

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924078A BRPI0924078A2 (pt) 2009-01-22 2009-01-22 n-glicanos contendo galactose-alfa-1,3-galactose em produtos de glicoproteína derivados de células de cho.

Country Status (15)

Country Link
US (3) US8586356B2 (pt)
EP (1) EP2389586B2 (pt)
JP (1) JP2012515922A (pt)
KR (1) KR20110119702A (pt)
CN (1) CN102292640B (pt)
AU (1) AU2009338190C1 (pt)
BR (1) BRPI0924078A2 (pt)
CA (1) CA2749281C (pt)
IL (1) IL213715A (pt)
MX (1) MX2011007545A (pt)
NZ (1) NZ593816A (pt)
RU (1) RU2484142C2 (pt)
SG (1) SG173078A1 (pt)
WO (1) WO2010085251A1 (pt)
ZA (1) ZA201104753B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110119702A (ko) 2009-01-22 2011-11-02 모멘타 파머슈티컬스 인코포레이티드 Cho 세포에서 유도된 글리코단백질 생성물에서의 갈락토오스-알파-1,3-갈락토오스-함유 n-글리칸
ES2605677T3 (es) 2009-11-11 2017-03-15 Momenta Pharmaceuticals, Inc. Glucosiltransferasa de hámster chino y métodos relacionados
US20130243744A1 (en) * 2011-01-06 2013-09-19 Michael J. Betenbaugh Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
JP2012189439A (ja) * 2011-03-10 2012-10-04 Sumitomo Bakelite Co Ltd 糖鎖試料の製造方法
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012158932A2 (en) * 2011-05-18 2012-11-22 University Of Massachusetts REMOVAL OF α-GAL EPITOPES FROM THERAPEUTIC GLYCOPROTEINS FOR AVOIDING INTERACTION WITH THE ANTI-GAL ANTIBODY
US8980583B2 (en) 2011-06-30 2015-03-17 Sigma-Aldrich Co. Llc Cells deficient in CMP-N-acetylneuraminic acid hydroxylase and/or glycoprotein alpha-1,3-galactosyltransferase
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2722673B1 (en) 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
CN105358577A (zh) * 2013-02-13 2016-02-24 法国化学与生物科技实验室 具有经修饰的糖基化的西妥昔单抗及其用途
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
ES2802274T3 (es) 2013-05-02 2021-01-18 Momenta Pharmaceuticals Inc Glicoproteínas sialiladas
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US11275090B2 (en) 2014-11-19 2022-03-15 Amgen Inc. Quantitation of glycan moiety in recombinant glycoproteins
CN105820248A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型抗egfr单克隆抗体的制备方法及应用
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3397282A4 (en) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS RELATING TO BIOLOGICA
US12595454B2 (en) 2018-09-06 2026-04-07 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
US20210353752A1 (en) 2018-10-11 2021-11-18 Momenta Pharmaceuticals, Inc. Treatment with highly silylated igg compositions
EA202191253A1 (ru) * 2018-11-08 2021-12-07 МИДОРИ ЮЭсЭй, ИНК. Способы количественного определения олигосахаридных препаратов
IL284374B2 (en) * 2018-12-31 2025-10-01 Momenta Pharmaceuticals Inc Methods for producing ozatekinumab
US11267853B2 (en) * 2019-01-28 2022-03-08 University Of Rhode Island Board Of Trustees Carbohydrate tethering at cell surfaces to induce immune response
CN109932445A (zh) * 2019-03-19 2019-06-25 北京泰德制药股份有限公司 一种糖蛋白多种电荷异构体n糖链结构的评价方法
CA3174533A1 (en) * 2020-03-05 2021-09-10 Momenta Pharmaceuticals, Inc. Methods of making hyper-sialylated immunoglobulin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527681A (en) * 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU8007791A (en) 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
RU2123338C1 (ru) * 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5871997A (en) 1994-07-21 1999-02-16 Alexion Pharmaceuticals, Inc. Methods and compositions for protecting retroviral vector particles and producer cells from inactivation by complement via reduction of the expression or recognition of galactose alpha (1,3) galactosyl epitopes
US5695937A (en) * 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
KR20040032105A (ko) 2001-06-04 2004-04-14 엠엘 래보러토리즈 피엘씨 재조합 단백질의 조성물 및 재조합 단백질의 고수준대규모 생산방법
US7651847B2 (en) * 2004-06-22 2010-01-26 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of cancer
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
JP4808542B2 (ja) * 2006-04-27 2011-11-02 公益財団法人野口研究所 糖鎖異性体を分離同定する質量分析法
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
ES2626080T3 (es) 2007-04-16 2017-07-21 Momenta Pharmaceuticals, Inc. Caracterización de N-glicanos utilizando exoglicosidasas
KR20110119702A (ko) 2009-01-22 2011-11-02 모멘타 파머슈티컬스 인코포레이티드 Cho 세포에서 유도된 글리코단백질 생성물에서의 갈락토오스-알파-1,3-갈락토오스-함유 n-글리칸

Also Published As

Publication number Publication date
AU2009338190A1 (en) 2011-07-14
US20160053292A1 (en) 2016-02-25
EP2389586A1 (en) 2011-11-30
IL213715A (en) 2016-02-29
JP2012515922A (ja) 2012-07-12
CN102292640A (zh) 2011-12-21
MX2011007545A (es) 2011-10-28
WO2010085251A1 (en) 2010-07-29
SG173078A1 (en) 2011-08-29
KR20110119702A (ko) 2011-11-02
EP2389586B2 (en) 2018-01-24
RU2011134491A (ru) 2013-02-27
US20110045496A1 (en) 2011-02-24
US8586356B2 (en) 2013-11-19
NZ593816A (en) 2012-11-30
ZA201104753B (en) 2012-12-27
US10023894B2 (en) 2018-07-17
EP2389586B1 (en) 2014-06-25
IL213715A0 (en) 2011-07-31
CA2749281A1 (en) 2010-07-29
CN102292640B (zh) 2014-07-02
AU2009338190B2 (en) 2014-04-10
US20140045212A1 (en) 2014-02-13
RU2484142C2 (ru) 2013-06-10
AU2009338190C1 (en) 2014-07-17
CA2749281C (en) 2016-11-29

Similar Documents

Publication Publication Date Title
BRPI0924078A2 (pt) n-glicanos contendo galactose-alfa-1,3-galactose em produtos de glicoproteína derivados de células de cho.
BRPI1009416A2 (pt) célula solar.
BR112012000107A2 (pt) receptores de células t.
HRP20150107T1 (xx) Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
AP2011005548A0 (en) Heterogeneous hydrogen-catalyst reactor.
BRPI0911695A2 (pt) conjunto de barbear
EP2262624A4 (en) shaving
BRPI1011965A2 (pt) estrutura de entressola.
BRPI0914208A2 (pt) célula de eletrólise, e, método
BRPI1007507A2 (pt) recipiente de dispensação, e, acessório fixado a um recipiente de dispensação.
AP2010005473A0 (en) Solar stills.
BRPI1007811A2 (pt) nacela de turborreator, e, turborreator
FR2937889B1 (fr) Installation de nettoyage de recipients.
IT1393382B1 (it) Tappo per serbatoi, in particolare per motocicli.
BRPI1013157A2 (pt) meio de fixação.
BR112012001062A2 (pt) laminados com microtextura.
FR2941674B1 (fr) Nacelle de turboreacteur.
IT1392509B1 (it) Dispositivo di protezione, con effetto aerodinamico, per motoveicolo.
CL2008001260S1 (es) Botella.
BR112012002307A2 (pt) mecanismo de came.
IT1394641B1 (it) Struttura di rasoio perfezionato.
FI20096171L (fi) Menetelmä hissijärjestelmän yhteydessä, sekä hissijärjestelmä
BR112012001500A2 (pt) produto moldado por painés automotivos.
IT1396618B1 (it) Contenitore per bombola.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL